Journal
NATURE CANCER
Volume 2, Issue 12, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s43018-021-00274-w
Keywords
-
Categories
Funding
- National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust [RMCC32]
- Cancer Research UK (CRUK) [C50947/A18176]
- Francis Crick Institute - CRUK [FC001988, FC001218, FC001099, FC001002, FC001078, FC001169, FC001030, FC011104]
- UK Medical Research Council [FC001988, FC001218, FC001099, FC001002, FC001078, FC001169, FC001030, FC011104]
- Wellcome Trust [FC001988, FC001218, FC001099, FC001002, FC001078, FC001169, FC001030, FC011104]
- NIHR Biomedical Research Centre at the Royal Marsden Hospital
- ICR [A109]
- Royal Marsden NHS Foundation Trust
- Royal Marsden Cancer Charity
- ESMO clinical research fellowship
- Rosetrees [M926]
- European Union [892360]
- CRUK Clinician PhD Fellowship award
- Rosetrees Charity [M829]
- CRUK [C50947/A18176, FC0010218]
- Institute of Cancer Research [A109]
- Kidney and Melanoma Cancer Fund of the Royal Marsden Cancer Charity
- Rosetrees Trust [A2204]
- Ventana Medical Systems [10467, 10530]
- National Institutes of Health (US)
- Melanoma Research Alliance
- Janssen-Cilag
- CRUK (TRACERx, PEACE and CRUK Cancer Immunotherapy Catalyst Network)
- CRUK Lung Cancer Centre of Excellence [C11496/A30025]
- Rosetrees Trust
- Butterfield Trust
- Stoneygate Trust
- Novo Nordisk Foundation [ID16584]
- Royal Society Professorship Enhancement award [RP/EA/180007]
- NIHR Biomedical Research Centre at University College London Hospitals
- CRUK University College London Centre
- Experimental Cancer Medicine Centre
- Breast Cancer Research Foundation [BCRF 20-157]
- Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational research grant [SU2C-AACR-DT23-17]
- Stand Up To Cancer is a division of the Entertainment Industry Foundation
- ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union's Horizon 2020 research and innovation program [835297]
- Royal Society Napier Research Professor [RP150154]
- Francis Crick Institute
- Wellcome [FC0010218, 203135, 222754]
- UKRI [FC0010218]
- South African MRC
- Marie Curie Actions (MSCA) [892360] Funding Source: Marie Curie Actions (MSCA)
Ask authors/readers for more resources
A cohort study evaluated 585 cancer patients following vaccination with BNT162b2 or AZD1222 vaccines, finding lower antibody responses in patients with hematological malignancies compared to those with solid tumors. Patients with hematological malignancies also had reduced neutralizing antibody responses compared to individuals without cancer. The study highlights the importance of managing cancer patients during the ongoing COVID-19 pandemic.
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available